EGFR and non-small cell lung carcinoma: Prior studies have consistently linked acquired TP53 and RB1 mutations to histologic transformation and poorer clinical outcomes.10,24 Additionally, EGFR-mutant NSCLC patients who harbored concurrent PIK3CA mutations exhibited significantly shorter PFS and OS when treated with EGFR-TKIs.25